Corteva
CTVA
$79.46
+1.13%
Corteva, Inc. is a global agricultural inputs company, formed in 2019 as a spin-off from DowDuPont, and operates in the Agricultural Inputs industry, primarily producing seeds and crop protection products. The company is a market leader in seed development and crop protection, with a strong focus on innovation and a global footprint, though roughly half of its revenue comes from North America. Currently, the investor narrative centers on the planned spin-off of its seeds business into a new entity named Vylor in late 2026, which will leave the remaining crop protection business as a pure-play company. This strategic transformation, along with recent quarterly earnings that showed a strong recovery in Q1 2026, is driving attention and debate around the stock's future growth and margin potential.…
CTVA
Corteva
$79.46
Investment Opinion: Should I buy CTVA Today?
Based on the analysis, I rate CTVA as a Buy. The thesis is that Corteva's strong Q1 2026 revenue growth of 11.05%, combined with a low debt-to-equity ratio of 0.107 and a forward PE of 18.61x, offers an attractive risk-reward, especially with the potential value unlock from the spin-off. Analyst consensus is a Buy with an average target price of $92.40, implying ~20.5% upside from the current price of $76.68.
Sign up to view all
CTVA 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The company's strong Q1 2026 performance, low leverage, and attractive forward valuation support a positive outlook. However, the stock's underperformance relative to the market and the execution risks of the spin-off warrant caution. If the company continues to deliver double-digit revenue growth and the spin-off proceeds smoothly, the stock could re-rate higher. Conversely, any setbacks could lead to a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $92.10 and implied upside of +15.9% versus the current price.
Average Target
$92.10
0 analysts
Implied Upside
+15.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$78 - $103
Analyst target range
The target price range spans from a low of $78.00 to a high of $103.00, indicating a wide spread of $25, which reflects significant uncertainty about the company's future. The high target of $103 assumes successful execution of the spin-off and strong growth in the crop protection business, while the low target of $78 suggests concerns about margin compression or competitive pressures. Recent institutional ratings show no downgrades, with firms like Mizuho, Barclays, and Morgan Stanley maintaining positive stances, and UBS and Citigroup holding Neutral ratings. The wide target spread and the mix of ratings suggest that while the consensus is bullish, there is notable divergence in expectations, likely due to the upcoming spin-off and its implications.
Bulls vs Bears: CTVA Investment Factors
Corteva presents a mixed investment case. On the bullish side, the company delivered strong Q1 2026 revenue growth of 11.05%, maintains a low debt-to-equity ratio of 0.107, and trades at a forward PE of 18.61x, which is attractive relative to its growth potential. Analyst consensus is a Buy with an average target of $92.40, implying ~20% upside. However, the stock has significantly underperformed the market, with a 1-year return of only 6.69% versus the S&P 500's 20.37%, and its trailing PE of 41.89x reflects earnings volatility. The upcoming spin-off adds both opportunity and risk. Currently, the bull case has stronger evidence due to the improving fundamentals and reasonable forward valuation, but the key tension is whether the company can sustain its growth momentum and successfully execute the spin-off, which would validate the market's expectations and drive the stock toward the higher end of the target range.
Bullish
- Strong Q1 2026 Revenue Acceleration: Q1 2026 revenue grew 11.05% YoY to $4.905B, up from 4.4% growth in Q1 2025, indicating accelerating demand across both Seed and Crop Protection segments. This broad-based strength suggests market share gains or favorable pricing, supporting the investment case.
- Low Leverage and Healthy Balance Sheet: Debt-to-equity is only 0.107, and current ratio is 1.43, indicating strong liquidity and low financial risk. This provides financial flexibility for the upcoming spin-off and potential investments in growth initiatives.
- Attractive Forward Valuation: Forward PE of 18.61x is significantly lower than trailing PE of 41.89x, implying the market expects substantial earnings growth. With analyst consensus EPS estimate of $5.29 for next year, the stock appears reasonably priced relative to growth.
- Positive Analyst Sentiment and Upside: Analyst consensus is 'Buy' with an average target price of $92.40, representing ~20.5% upside from the current price of $76.68. No recent downgrades and a recommendation mean of 1.76 (between Buy and Outperform) reflect institutional confidence.
Bearish
- Significant Underperformance vs. Market: CTVA's 1-year return of +6.69% lags the S&P 500's +20.37% gain, and relative strength is negative across all timeframes (1M: -12.05%, 3M: -11.76%, 1Y: -13.68%). This suggests persistent selling pressure and investor skepticism.
- High Trailing PE and Earnings Volatility: Trailing PE of 41.89x is elevated, reflecting the company's volatile earnings, with losses in Q3 and Q4 2025. The market is pricing in a strong recovery, but any miss could lead to multiple compression.
- Seasonal and Cyclical Revenue Concentration: Revenue is highly seasonal, with Q2 2025 revenue of $6.456B versus Q3 2025 of $2.618B, creating lumpy cash flows. Additionally, ~50% of revenue comes from North America, exposing the company to regional agricultural and weather risks.
- Spin-off Execution Risks: The planned spin-off of the Seeds business introduces operational complexity, potential tax implications, and uncertainty about the remaining company's growth profile. Any delays or unfavorable terms could negatively impact the stock.
CTVA Technical Analysis
Corteva's stock has experienced a volatile but generally upward trend over the past year, with a 1-year price change of +6.69%, though it has significantly underperformed the S&P 500's +20.37% gain. The current price of $76.68 sits at approximately 84.3% of its 52-week range (low: $60.535, high: $90.97), indicating the stock is closer to its highs but has pulled back from the peak. This positioning suggests that while the longer-term trend has been positive, the stock is not at overbought levels and may have room to run if momentum resumes.
Beta
0.57
0.57x market volatility
Max Drawdown
-18.7%
Largest decline past year
52-Week Range
$61-$91
Price range past year
Annual Return
+8.9%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | -8.6% | +1.9% |
| 3m | -0.1% | +2.3% |
| 6m | +4.1% | +10.6% |
| 1y | +8.9% | +19.5% |
| ytd | +17.3% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Corteva's revenue trajectory shows a mixed but improving picture. In Q1 2026, revenue reached $4.905 billion, up 11.05% year-over-year, marking a strong acceleration from the prior year's Q1 growth of 4.4% (calculated from $4.417 billion in Q1 2025). However, the multi-quarter trend is uneven: Q2 2025 revenue was $6.456 billion, Q3 2025 fell to $2.618 billion, and Q4 2025 was $3.910 billion, reflecting the seasonal nature of the agricultural business. The Q1 2026 growth was driven by both segments, with Seed revenue of $3.023 billion and Crop Protection revenue of $1.882 billion, indicating broad-based strength. This growth suggests the company is gaining market share or benefiting from favorable pricing, which is a positive sign for the investment case.
Quarterly Revenue
$4.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
48.5%
Latest Quarter
Free Cash Flow
$2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Given that Corteva's trailing twelve-month net income is positive (Q1 2026 net income of $720 million, but Q4 2025 and Q3 2025 were losses, so TTM net income is approximately $1.16 billion), the primary valuation metric selected is the PE ratio. The trailing PE is 41.89x, while the forward PE is 18.61x, implying the market expects significant earnings growth in the next year. This gap suggests that the market is pricing in a strong recovery from the recent losses, which is consistent with the Q1 2026 earnings beat and the planned spin-off that may unlock value.
PE
41.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate. Corteva's debt-to-equity ratio is low at 0.107, and the current ratio of 1.43 indicates adequate liquidity, but the company's earnings are volatile, with net losses in Q3 and Q4 2025. The trailing PE of 41.89x is elevated, implying high expectations for earnings recovery; any shortfall could lead to a sharp de-rating. Additionally, free cash flow of $2.046B TTM is positive but may be insufficient to fund both the spin-off and growth investments, potentially increasing leverage. Revenue concentration in North America (~50%) exposes the company to regional agricultural cycles, weather events, and trade policy changes, which could cause significant quarterly swings.